Azer-cel not checked
Imugene Limited · Allogeneic Anti-CD19 CAR T cells · PBCAR0191
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Main trialPhase 1
- “This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell NHL and CLL/SLL.”In the company’s words, NCT03666000 on ClinicalTrials.gov
- Other names
- Allogeneic Anti-CD19 CAR T cells · PBCAR0191
Other drugs for Non-Hodgkin Lymphoma
- GlofitamabRoche · Phase 3
- ObinutuzumabRoche · Phase 3
- TocilizumabRoche · Phase 3
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
- XNW5004Evopoint Biosciences Inc. · Phase 3
Coming up1
- Jun 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Jun 2027 | Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026